Tag: Psilocybin

US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company ...

Now part of Rhelion Life Sciences, Canadian pharmaceutical developer Filament Health is supplying naturally derived psilocybin for clinical research worldwide, ...

From melting clocks to impossible landscapes, Salvador Dalí's exploration of dreams and the unconscious offers an intriguing perspective on how ...

Canadian pharmaceutical manufacturer Optimi Health has appointed experienced pharmaceutical executive Adrian Jones to lead its Australian operations, with a focus ...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...

Early clinical data presented at the ECNP Congress show predictable psychedelic effects and measurable changes in brain activity, as the ...

As psychedelic-assisted therapy develops, researchers are investigating how music, visual imagery and treatment environments influence patients' experiences, and whether these ...

The Canadian pharmaceutical manufacturer says it is supplying 26 Australian clinics with naturally derived psilocybin and is targeting further growth ...

The Australian-founded biotechnology company is progressing three investigational treatments, including a synthetic psilocybin therapy for generalised anxiety disorder, as its ...

The three-day conference, hosted by entrepreneur Dave Asprey, brings together researchers, clinicians and business leaders to discuss psychedelic therapies, neuroscience ...